Assessment of the metabolism of therapeutic proteins and antibodies

Expert Opinion on Drug Metabolism and Toxicology

Volumn 10, Issue 8, 2014, Pages 1079-1091

  Ezan, Eric ^a   Becher, François ^b   Fenaille, François ^b  

^a DIF   (France)

^b SERVICE DE CHIMIE BIOORGANIQUE ET DE MARQUAGE   (France)

Author keywords

Antibody drug conjugate; Glycosylation; Immunoassays; Mass spectrometry; Metabolism; Pharmacokinetics; Radioactivity; Recombinant; Therapeutic proteins

Indexed keywords

ANTIBODY CONJUGATE; BIOLOGICAL PRODUCT; DRUG ANTIBODY; GLYCOSYLATED PROTEIN; RECOMBINANT ANTIBODY; RECOMBINANT PROTEIN; TRACER; ANTIBODY; LIGAND;

ANALYTIC METHOD; BIOTRANSFORMATION; DRUG CONJUGATION; DRUG EFFICACY; DRUG METABOLISM; DRUG TRANSFORMATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; LIMIT OF QUANTITATION; MASS SPECTROMETRY; NONHUMAN; PROTEIN ANALYSIS; PROTEIN GLYCOSYLATION; PROTEIN METABOLISM; PROTEIN MODIFICATION; RECEPTOR BINDING ASSAY; REVIEW; ANIMAL; DRUG DELIVERY SYSTEM; DRUG DESIGN; METABOLISM; PROCEDURES;

ANIMALS; ANTIBODIES; BIOLOGICAL PRODUCTS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; LIGANDS; MASS SPECTROMETRY; RECOMBINANT PROTEINS;

EID: 84904359540     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2014.925878     Document Type: Review

References (93)

1. FDA. Guidance for Industry: S6 preclinical safety evaluation of biotechnology-derived pharmaceuticals. Food and Drug Administration. 1997. Available from: http://www.fda. gov/downloads/regulatoryinformation/guidances/ ucm129171.pdf
2. Kontermann RE. Strategies for extended serum half-life of protein therapeutics. Curr Opin Biotechnol 2011;22:868-76
3. EMEA. Guideline on the clinical investigation of the pharmacokinetics of therapeutic proteins. European Medecines Agency. 2007. Available from: http://www.ema. europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/ 09/WC500003029.pdf
4. Katsila T, Siskos AP, Tamvakopoulos C. Peptide and protein drugs: the study of their metabolism and catabolism by mass spectrometry. Mass Spectrom Rev 2012;31:110-33
5. Xu X, Vugmeyster Y. Challenges and opportunities in absorption, distribution, metabolism, and excretion studies of therapeutic biologics. AAPS J 2012;14:781-91
6. Hamuro LL, Kishnani NS. Metabolism of biologics: biotherapeutic proteins. Bioanalysis 2012;4:189-95
7. Lee JW. ADME of monoclonal antibody biotherapeutics: knowledge gaps and emerging tools. Bioanalysis 2013;5:2003-14
8. Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 2008;84:548-58
9. Ezan E. Pharmacokinetic studies of protein drugs: past, present and future. Adv Drug Deliv Rev 2013;65:1065-73
10. Wang W, Chen N, Shen X, et al. Lymphatic transport and catabolism of therapeutic proteins after subcutaneous administration to rats and dogs. Drug Metab Dispos 2012;40:952-62
11. Zou Y, Bateman TJ, Adreani C, et al. Lymphatic absorption, metabolism, and excretion of a therapeutic peptide in dogs and rats. Drug Metab Dispos 2013;41:2206-14
12. Waldmann TA, Lugli E, Roederer M, et al. Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques. Blood 2011;117:4787-95
13. Golor G, sen-Kennedy D, Haffner S, et al. Safety and pharmacokinetics of a recombinant fusion protein linking coagulation factor VIIa with albumin in healthy volunteers. J Thromb Haemost 2013;11:1977-85
14. Uhl W, Zuhlsdorf M, Koernicke T, et al. Safety, tolerability, and pharmacokinetics of the novel alphavintegrin antibody EMD 525797 (DI17E6) in healthy subjects after ascending single intravenous doses. Invest New Drugs 2014;32(2):347-54
15. Segrave AM, Mager DE, Charman SA, et al. Pharmacokinetics of recombinant human leukemia inhibitory factor in sheep. J Pharmacol Exp Ther 2004;309:1085-92
16. Chapel S, Veng-Pedersen P, Hohl RJ, et al. Changes in erythropoietin pharmacokinetics following busulfaninduced bone marrow ablation in sheep: evidence for bone marrow as a major erythropoietin elimination pathway. J Pharmacol Exp Ther 2001;298:820-4
17. Schellekens H. How to predict and prevent the immunogenicity of therapeutic proteins. Biotechnol Annu Rev 2008;14:191-202
18. Vugmeyster Y, Xu X, Theil FP, et al. Pharmacokinetics and toxicology of therapeutic proteins: advances and challenges. World J Biol Chem 2012;3:73-92
19. Kato M, Miura K, Kamiyama H, et al. Immunological response to repeated administration of recombinant human erythropoietin in rats: biphasic effect on its pharmacokinetics. Drug Metab Dispos 1997;25:1039-44
20. Fischer KG, Liebe V, Hudek R, et al. Anti-hirudin antibodies alter pharmacokinetics and pharmacodynamics of recombinant hirudin. Thromb Haemost 2003;89:973-82
21. Tagliaro F, Dorizzi R, Luisetto G. Effect of antibodies to calcitonin on the pharmacokinetics and the pharmacodynamics of the hormone. Horm Metab Res 1995;27:31-4
22. Christensen EI. Rapid protein uptake and digestion in proximal tubule lysosomes. Kidney Int 1976;10:301-10
23. Saito A, Sato H, Iino N, Takeda T. Molecular mechanisms of receptormediated endocytosis in the renal proximal tubular epithelium. J Biomed Biotechnol 2010;2010:403272
24. Postel-Vinay MC, Kayser C, Desbuquois B. Fate of injected human growth hormone in the female rat liver in vivo. Endocrinology 1982;111:244-51
25. Opanasopit P, Nishikawa M, Yamashita F, et al. Pharmacokinetic analysis of lectin-dependent biodistribution of fucosylated bovine serum albumin: a possible carrier for Kupffer cells. J Drug Target 2001;9:341-51
26. Higuchi Y, Nishikawa M, Kawakami S, et al. Uptake characteristics of mannosylated and fucosylated bovine serum albumin in primary cultured rat sinusoidal endothelial cells and Kupffer cells. Int J Pharm 2004;287:147-54
27. Jelkmann W. The enigma of the metabolic fate of circulating erythropoietin (Epo) in view of the pharmacokinetics of the recombinant drugs rhEpo and NESP. Eur J Haematol 2002;69:265-74
28. Egrie JC, Dwyer E, Browne JK, et al. Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol 2003;31:290-9
29. Rath T, Kuo TT, Baker K, et al. The immunologic functions of the neonatal Fc receptor for IgG. J Clin Immunol 2013;33(Suppl 1):S9-17
30. Chen X, Zaro JL, Shen WC. Pharmacokinetics of recombinant bifunctional fusion proteins. Expert Opin Drug Metab Toxicol 2012;8:581-95
31. Hager T, Spahr C, Xu J, et al. Differential enzyme-linked immunosorbent assay and ligand-binding mass spectrometry for analysis of biotransformation of protein therapeutics: application to various FGF21 modalities. Anal Chem 2013;85:2731-8
32. Pasut G, Veronese FM. State of the art in PEGylation: the great versatility achieved after forty years of research. J Control Release 2012;161:461-72
33. Nadeau RW, Satoh H, Scheide S, et al. A comparison of mass balance, pharmacokinetics and disposition of [14C(U)]- and [125I]recombinant human interleukin-2 in cynomolgus monkeys. Drug Metab Dispos 1995;23:904-9
34. Wang H, Wang L, Cao K, et al. Development of a carbon-14 labeling approach to support disposition studies with a pegylated biologic. Drug Metab Dispos 2012;40:1677-85
35. Xiang H, Nguyen CB, Kelley SK, et al. Tissue distribution, stability, and pharmacokinetics of Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand in human colon carcinoma COLO205 tumor-bearing nude mice. Drug Metab Dispos 2004;32:1230-8
36. Ferraiolo BL, Moore JA, Crase D, et al. Pharmacokinetics and tissue distribution of recombinant human tumor necrosis factor-alpha in mice. Drug Metab Dispos 1988;16:270-5
37. Mesmin C, Renvoise M, Becher F, et al. MS-based approaches to unravel the molecular complexity of proproteinderived biomarkers and support their quantification: the examples of B-type natriuretic peptide and apelin peptides. Bioanalysis 2012;4:2851-63
38. Richter WF, Gallati H, Schiller CD. Animal pharmacokinetics of the tumor necrosis factor receptor-immunoglobulin fusion protein lenercept and their extrapolation to humans. Drug Metab Dispos 1999;27:21-5
39. Chen SA, Sawchuk RJ, Brundage RC, et al. Plasma and lymph pharmacokinetics of recombinant human interleukin-2 and polyethylene glycolmodified interleukin-2 in pigs. J Pharmacol Exp Ther 2000;293:248-59
40. Pascual MH, Verdier P, Malette P, et al. Validation of an immunoassay to selectively quantify the naked antibody of a new Antibody Drug Conjugate - SAR566658 - for pharmacokinetic interpretation improvement. J Immunol Methods 2013;396:140-6
41. Stephan JP, Chan P, Lee C, et al. Anti- CD22-MCC-DM1 and MC-MMAF conjugates: impact of assay format on pharmacokinetic parameters determination. Bioconjug Chem 2008;19:1673-83
42. Srebalus Barnes CA, Lim A. Applications of mass spectrometry for the structural characterization of recombinant protein pharmaceuticals. Mass Spectrom Rev 2007;26:370-88
43. Beck A, Wagner-Rousset E, Ayoub D, et al. Characterization of therapeutic antibodies and related products. Anal Chem 2013;85:715-36
44. Domon B, Aebersold R. Mass spectrometry and protein analysis. Science 2006;312:212-17
45. Macht M. Mass spectrometric top-down analysis of proteins. Bioanalysis 2009;1:1131-48
46. Macht M. Top-down characterization of biopharmaceuticals. Trends Anal Chem 2013;48:62-71
47. Savaryn JP, Catherman AD, Thomas PM, et al. The emergence of top-down proteomics in clinical research. Genome Med 2013;5:53
48. van Dongen WD, Niessen WM. LC-MS systems for quantitative bioanalysis. Bioanalysis 2012;4:2391-9
49. van den Broek I, Niessen WM, van Dongen WD. Bioanalytical LC-MS/MS of protein-based biopharmaceuticals. J Chromatogr B Analyt Technol Biomed Life Sci 2013;929:161-79
50. Hagman C, Ricke D, Ewert S, et al. Absolute quantification of monoclonal antibodies in biofluids by liquid chromatography-tandem mass spectrometry. Anal Chem 2008;80:1290-6
51. Heudi O, Barteau S, Zimmer D, et al. Towards absolute quantification of therapeutic monoclonal antibody in serum by LC-MS/MS using isotopelabeled antibody standard and protein cleavage isotope dilution mass spectrometry. Anal Chem 2008;80:4200-7
52. Yang Z, Hayes M, Fang X, et al. LCMS/MS approach for quantification of therapeutic proteins in plasma using a protein internal standard and 2D-solid-phase extraction cleanup. Anal Chem 2007;79:9294-301
53. Dubois M, Fenaille F, Clement G, et al. Immunopurification and mass spectrometric quantification of the active form of a chimeric therapeutic antibody in human serum. Anal Chem 2008;80:1737-45
54. Becher F, Pruvost A, Clement G, et al. Quantification of small therapeutic proteins in plasma by liquid chromatography-tandem mass spectrometry: application to an elastase inhibitor EPI-hNE4. Anal Chem 2006;78:2306-13
55. Ji QC, Rodila R, Gage EM, El-Shourbagy TA. A strategy of plasma protein quantitation by selective reaction monitoring of an intact protein. Anal Chem 2003;75:7008-14
56. Li H, Ortiz R, Tran L, et al. General LC-MS/MS method approach to quantify therapeutic monoclonal antibodies using a common whole antibody internal standard with application to preclinical studies. Anal Chem 2012;84:1267-73
57. Mesmin C, Fenaille F, Ezan E, Becher F. MS-based approaches for studying the pharmacokinetics of protein drugs. Bioanalysis 2011;3:477-80
58. Ezan E, Dubois M, Becher F. Bioanalysis of recombinant proteins and antibodies by mass spectrometry. Analyst 2009;134:825-34
59. Dubois M, Becher F, Herbet A, Ezan E. Immuno-mass spectrometry assay of EPIHNE4, a recombinant protein inhibitor of human elastase. Rapid Commun Mass Spectrom 2007;21:352-8
60. Shi T, Fillmore TL, Sun X, et al. Antibody-free, targeted massspectrometric approach for quantification of proteins at low picogram per milliliter levels in human plasma/serum. Proc Natl Acad Sci USA 2012;109:15395-400
61. Fernandez OM, James IT, Kabir M, et al. Clinical pharmacokinetic assessment of an anti-MAdCAM monoclonal antibody therapeutic by LCMS/MS. Anal Chem 2012;84:5959-67
62. Xu Y, Mehl JT, Bakhtiar R, Woolf EJ. Immunoaffinity purification using anti- PEG antibody followed by twodimensional liquid chromatography/tandem mass spectrometry for the quantification of a PEGylated therapeutic peptide in human plasma. Anal Chem 2010;82:6877-86
63. Hoofnagle AN, Wener MH. The fundamental flaws of immunoassays and potential solutions using tandem mass spectrometry. J Immunol Methods 2009;347:3-11
64. Zhang CX, Weber BV, Thammavong J, et al. Identification of carboxyl-terminal peptide fragments of parathyroid hormone in human plasma at lowpicomolar levels by mass spectrometry. Anal Chem 2006;78:1636-43
65. Thevis M, Thomas A, Schanzer W. Mass spectrometric determination of insulins and their degradation products in sports drug testing. Mass Spectrom Rev 2008;27:35-50
66. Hall MP, Gegg C, Walker K, et al. Ligand-binding mass spectrometry to study biotransformation of fusion protein drugs and guide immunoassay development: strategic approach and application to peptibodies targeting the thrombopoietin receptor. AAPS J 2010;12:576-85
67. Hecht R, Li YS, Sun J, et al. Rationale-based engineering of a potent long-acting FGF21 analog for the treatment of Type 2 diabetes. PLoS One 2012;7:e49345
68. Wroblewski VJ, Witcher DR, Becker GW, et al. Decoy receptor 3 (DcR3) is proteolytically processed to a metabolic fragment having differential activities against Fas ligand and LIGHT. Biochem Pharmacol 2003;65:657-67
69. Wroblewski VJ, McCloud C, Davis K, et al. Pharmacokinetics, metabolic stability, and subcutaneous bioavailability of a genetically engineered analog of DcR3, FLINT [DcR3(R218Q)], in cynomolgus monkeys and mice. Drug Metab Dispos 2003;31:502-7
70. Walsh G. Post-translational modifications of protein biopharmaceuticals. Drug Discov Today 2010;15:773-80
71. Ashwell G, Harford J. Carbohydrate-specific receptors of the liver. Annu Rev Biochem 1982;51:531-54
72. Beck A, Reichert JM. Marketing approval of mogamulizumab: a triumph for glyco-engineering. MAbs 2012;4:419-25
73. Stahl PD. The mannose receptor and other macrophage lectins. Curr Opin Immunol 1992;4:49-52
74. Jones AJ, Papac DI, Chin EH, et al. Selective clearance of glycoforms of a complex glycoprotein pharmaceutical caused by terminal N-acetylglucosamine is similar in humans and cynomolgus monkeys. Glycobiology 2007;17:529-40
75. Chen X, Liu YD, Flynn GC. The effect of Fc glycan forms on human IgG2 antibody clearance in humans. Glycobiology 2009;19:240-9
76. Goetze AM, Liu YD, Zhang Z, et al. High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans. Glycobiology 2011;21:949-59
77. Hong Q, Lebrilla CB, Miyamoto S, Ruhaak LR. Absolute quantitation of immunoglobulin G and its glycoforms using multiple reaction monitoring. Anal Chem 2013;85:8585-93
78. Xu K, Liu L, Saad OM, et al. Characterization of intact antibody-drug conjugates from plasma/serum in vivo by affinity capture capillary liquid chromatography-mass spectrometry. Anal Biochem 2011;412:56-66
79. Kaur S, Xu K, Saad OM, et al. Bioanalytical assay strategies for the development of antibody-drug conjugate biotherapeutics. Bioanalysis 2013;5:201-26
80. Wakankar A, Chen Y, Gokarn Y, Jacobson FS. Analytical methods for physicochemical characterization of antibody drug conjugates. MAbs 2011;3:161-72
81. Shen BQ, Xu K, Liu L, et al. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat Biotechnol 2012;30:184-9
82. Chen J, Yin S, Wu Y, Ouyang J. Development of a native nanoelectrospray mass spectrometry method for determination of the drug-to-antibody ratio of antibody-drug conjugates. Anal Chem 2013;85:1699-704
83. Peterson AC, Russell JD, Bailey DJ, et al. Parallel reaction monitoring for high resolution and high mass accuracy quantitative, targeted proteomics. Mol Cell Proteomics 2012;11:1475-88
84. Gallien S, Duriez E, Crone C, et al. Targeted proteomic quantification on quadrupole-orbitrap mass spectrometer. Mol Cell Proteomics 2012;11:1709-23
85. Shliaha PV, Bond NJ, Gatto L, Lilley KS. Effects of traveling wave ion mobility separation on data independent acquisition in proteomics studies. J Proteome Res 2013;12:2323-39
86. Cindric M, Cepo T, Galic N, et al. Structural characterization of PEGylated rHuG-CSF and location of PEG attachment sites. J Pharm Biomed Anal 2007;44:388-95
87. Seyfried BK, Siekmann J, Belgacem O, et al. MALDI linear TOF mass spectrometry of PEGylated (glyco) proteins. J Mass Spectrom 2010;45:612-17
88. Yoo C, Suckau D, Sauerland V, et al. Toward top-down determination of PEGylation site using MALDI in-source decay MS analysis. J Am Soc Mass Spectrom 2009;20:326-33
89. Forstenlehner IC, Holzmann J, Scheffler K, et al. A direct-infusion- and HPLC-ESI-orbitrap-MS approach for the characterization of intact PEGylated proteins. Anal Chem 2014;86:826-34
90. Warrack BM, Redding BP, Chen G, Bolgar MS. Determination of the molecular weight of poly(ethylene glycol) in biological samples by reversed-phase LC-MS with in-source fragmentation. Anal Bioanal Chem 2013;405:4283-7
91. Liu Q, De Felippis MR, Huang L. Method for characterization of PEGylated bioproducts in biological matrixes. Anal Chem 2013;85:9630-7
92. Caravella J, Lugovskoy A. Design of next-generation protein therapeutics. Curr Opin Chem Biol 2010;14:520-8
93. Kontos S, Hubbell JA. Drug development: longer-lived proteins. Chem Soc Rev 2012;41:2686-95